1. Scrip
  2. >>Therapy Areas

Ex-Novartis Exec Joins Checkpoint Agonist-Focused Biotech

Carolin Barth Is New CEO

 
• By Andrew McConaghie

The Oxford university spin-out MiroBio has a senior leadership team in place, and aims to have its first checkpoint agonists in the clinic in 2022. Scrip spoke to its CEO about its plans.

Oxford Science Park, Fletcher House and Winchester House
Miro Bio is headquartered at Oxford Science Park, UK

MiroBio, an emerging biotech focused on developing checkpoint agonist drugs has appointed Carolin Barth, former head of commercial and pipeline strategy, cell and gene therapy at Novartis, as its CEO.

The Oxford, UK-based company came out of stealth mode nearly two years ago with a $34m series A fundraising, and...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Dermatological

More from Therapy Areas

Scholar Rock Shows Muscle-Building PoC In Obesity

 
• By Jessica Merrill

The company said it intends to maintain a focus on rare neuromuscular disease with apitegromab but could consider partnering in obesity.

Spyre Takes Aim At Roche And J&J In Inflammatory Diseases

 
• By Andrew McConaghie

The US firm was already looking to compete in ulcerative colitis, but now expands its ambitions by moving into rheumatoid arthritis as well.

Draig Is All Fired Up To Transform Neuropsychiatric Field

 
• By Kevin Grogan

Wales-based group launches with $140m series A.